Epidemiology and Management of Parathyroid Gland Disorders in Spain over 15 Years: A Retrospective Multicentre Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Mar 11

PMID 32155210

Citations 9

Authors

Josep Darba

Alicia Marsa

Affiliations

Soon will be listed here.

Abstract

Parathyroid gland disorders are rare conditions with an incidence that displays great variability among populations. Its direct influence in calcium homeostasis originates variable symptoms that affect bone remodelling among other processes. This study aimed to provide data on the epidemiology and characteristics of patients admitted with these disorders in Spain between 2003 and 2017, and to analyse disease management and direct medical costs. Medical records in which a disorder of the parathyroid gland was registered as the admission motive were extracted from a nationwide hospital-discharge database via the Spanish Ministry of Health. Records from 12,903 patients were obtained, with predominance of female patients (74.70%) and of admissions due to hyperparathyroidism (90.23%). The number of patients admitted per year increased over the study period along the incidence of these disorders. The year 2017 incidence of hyperparathyroidism was 2.95 per 10,000, 4.03 per 10,000 in females and 1.37 in males; the same year, the incidence of hypoparathyroidism was 0.17 per 10,000. Length of hospital stay was significantly extended in patients with hypoparathyroidism (7.16 days), admitted mostly due to emergencies. Heart failure was diagnosed in more than 20% of admissions in patients with secondary and tertiary hyperparathyroidism and hypoparathyroidism, while this last group displayed the highest levels of mineral metabolism disruption. Parathyroidectomy was performed in 78.95% of all admissions for primary hyperparathyroidism. The total annual direct medical cost parathyroid gland disorders has increased over the study period, due to the increase of the costs associated to hyperparathyroidism, whereas the cost per patient remained relatively stable, with an average of €3,748, €3,430 and €3,737 for patients with hyperparathyroidism, hypoparathyroidism and other disorders of the parathyroid gland, respectively. This study provides novel data to extend the scarce available knowledge on parathyroid gland disorders' epidemiology and management in Spain.

Citing Articles

Surgical treatment of tertiary hyperparathyroidism: does one fit for all?.

Casella C, Guarneri C, Campanile M, Adhoute X, Gelera P, Morandi R Front Endocrinol (Lausanne). 2023; 14:1226917.

PMID: 38027172 PMC: 10652876. DOI: 10.3389/fendo.2023.1226917.

Robot-Assisted Parathyroidectomy Using Indocyanine Green (ICG) Fluorescence in Primary Hyperparathyroidism.

Park S, Choi Y, Hwang Y, Yi J Medicina (Kaunas). 2023; 59(8).

PMID: 37629746 PMC: 10456807. DOI: 10.3390/medicina59081456.

Hypoparathyroidism - management, information needs, and impact on daily living from the patients' perspective: results from a population-based survey.

Buttner M, Krogh D, Fuhrer D, Fuss C, Willenberg H, Luster M Hormones (Athens). 2023; 22(3):467-476.

PMID: 37380916 PMC: 10449945. DOI: 10.1007/s42000-023-00459-1.

Recent Trends in Hypoparathyroidism-Related Inpatient and Emergency Department Admissions and Costs in the United States.

Kaul S, Gosmanova E, Castriota F, Hitchens A, Candrilli S, Parikh R J Endocr Soc. 2023; 7(5):bvad050.

PMID: 37153700 PMC: 10157763. DOI: 10.1210/jendso/bvad050.

Stable Incidence and Increasing Prevalence of Primary Hyperparathyroidism in a Population-based Study in Scotland.

Soto-Pedre E, Newey P, Leese G J Clin Endocrinol Metab. 2023; 108(10):e1117-e1124.

PMID: 37022975 PMC: 10505547. DOI: 10.1210/clinem/dgad201.

References

Munoz Torres M, Jodar Gimeno E, Reyes Garcia R, Martinez Diaz Guerra G, Amado J, Gaztambide S . Results from a national survey on the management of primary hyperparathyroidism. J Endocrinol Invest. 2011; 35(11):957-63. DOI: 10.3275/8184. View

Yeh M, Ituarte P, Zhou H, Nishimoto S, Liu I, Harari A . Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013; 98(3):1122-9. PMC: 3590475. DOI: 10.1210/jc.2012-4022. View

Goldstein R, Blevins L, Delbeke D, Martin W . Effect of minimally invasive radioguided parathyroidectomy on efficacy, length of stay, and costs in the management of primary hyperparathyroidism. Ann Surg. 2000; 231(5):732-42. PMC: 1421061. DOI: 10.1097/00000658-200005000-00014. View

Koumakis E, Souberbielle J, Payet J, Sarfati E, Borderie D, Kahan A . Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int. 2014; 25(7):1963-8. DOI: 10.1007/s00198-014-2689-2. View

Michels T, Kelly K . Parathyroid disorders. Am Fam Physician. 2013; 88(4):249-57. View

Rodriguez Portillo M, Rodriguez-Ortiz M . Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. Rev Endocr Metab Disord. 2017; 18(1):79-95. DOI: 10.1007/s11154-017-9421-4. View

Yu N, Donnan P, Murphy M, Leese G . Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf). 2009; 71(4):485-93. DOI: 10.1111/j.1365-2265.2008.03520.x. View

Bilezikian J, Khan A, Potts Jr J . Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94(2):335-9. PMC: 3214274. DOI: 10.1210/jc.2008-1763. View

Bollerslev J, Schalin-Jantti C, Rejnmark L, Siggelkow H, Morreau H, Thakker R . MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur J Endocrinol. 2019; 181(3):P1-P19. PMC: 6598862. DOI: 10.1530/EJE-19-0316. View

10.

Clarke B . Epidemiology of primary hyperparathyroidism. J Clin Densitom. 2013; 16(1):8-13. DOI: 10.1016/j.jocd.2012.11.009. View

11.

Wermers R, Khosla S, Atkinson E, Achenbach S, Oberg A, Grant C . Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2005; 21(1):171-7. DOI: 10.1359/JBMR.050910. View

12.

Clarke B, Brown E, Collins M, Juppner H, Lakatos P, Levine M . Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab. 2016; 101(6):2284-99. PMC: 5393595. DOI: 10.1210/jc.2015-3908. View

13.

Diaz-Guerra G, Gimeno E, Reyes Garcia R, Gomez Saez J, Munoz-Torres M . [Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up]. Endocrinol Nutr. 2013; 60(8):456.e1-6. DOI: 10.1016/j.endonu.2013.01.015. View

14.

. [Law 14/2007, 3 July, on biomedical research (BOE, 4 July 2007)]. Rev Derecho Genoma Hum. 2008; (26):283-325. View

15.

Corbetta S, Mantovani G, Spada A . Metabolic Syndrome in Parathyroid Diseases. Front Horm Res. 2018; 49:67-84. DOI: 10.1159/000486003. View

16.

Pronai W, Rosenkranz A, Bock A, Klauser-Braun R, Jager C, Pendl G . Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study. Wien Klin Wochenschr. 2017; 129(9-10):317-328. PMC: 5429358. DOI: 10.1007/s00508-016-1153-z. View

17.

Mannstadt M, Bilezikian J, Thakker R, Hannan F, Clarke B, Rejnmark L . Hypoparathyroidism. Nat Rev Dis Primers. 2017; 3:17055. DOI: 10.1038/nrdp.2017.55. View

18.

Clarke B . Epidemiology and Complications of Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018; 47(4):771-782. DOI: 10.1016/j.ecl.2018.07.004. View

19.

Brandi M, Bilezikian J, Shoback D, Bouillon R, Clarke B, Thakker R . Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab. 2016; 101(6):2273-83. DOI: 10.1210/jc.2015-3907. View

20.

Messa P, Alfieri C . Secondary and Tertiary Hyperparathyroidism. Front Horm Res. 2019; 51:91-108. DOI: 10.1159/000491041. View